Comparative Tolerability And Efficacy Of Stavudine 30 Mg Versus Stavudine 40 Mg In Patients On Combination Antiretroviral Therapy In Kenya

Stavudine- containing regimens are currently the most widely used first-line anti-HIV treatment option in Kenya. This study compared the efficacy and tolerability of stavudine at two dose levels in patients attending a HIV Comprehensive Care Centre in Kenya. Data were collected retrospectively from the records of 810 adult patients. Fewer stavudine related adverse effects were seen in patients � 60 kg treated with 30 mg stavudine compared to those who received 40 mg (4.2 vs 16.7%, p < 0.001). Patients < 60 kg were more likely to experience drug toxicity than those � 60 kg when given 30 mg stavudine (12.8 vs 4.2%, p < 0.001). Occurrence of any adverse drug reaction was significantly associated with severe immunosuppression (HR =1.45, CI: 0.86 - 2.45, p < 0.001), co-morbidities (HR = 2.16, CI: 1.06 4.38, p < 0.001) and treatment with isoniazid (HR = 2.07, CI: 1.09 - 3.96, p < 0.001). The onset of drug related toxicities was principally in the first year of commencing therapy. Similar immunologic outcomes were demonstrated across all the treatment groups with median CD4 cell counts after 12 months of treatment more than doubling for patients in all the study cohorts. The findings support the use of combination antiretroviral therapy regimens containing low dose stavudine in Kenya.

[1]  P. Braitstein,et al.  Sustainability of First-Line Antiretroviral Regimens: Findings From a Large HIV Treatment Program in Western Kenya , 2010, Journal of acquired immune deficiency syndromes.

[2]  A. Westfall,et al.  Durability of Initial Antiretroviral Therapy in a Resource-Constrained Setting and the Potential Need for Zidovudine Weight-Based Dosing , 2009, Journal of acquired immune deficiency syndromes.

[3]  D. Hoover,et al.  Adult Clinical and Immunologic Outcomes of the National Antiretroviral Treatment Program in Rwanda During 2004-2005 , 2009, Journal of acquired immune deficiency syndromes.

[4]  K. Brinkman.  Stavudine in antiretroviral therapy: is this the end? , 2009, AIDS.

[5]  M. Boyd.  Improvements in antiretroviral therapy outcomes over calendar time , 2009, Current opinion in HIV and AIDS.

[6]  J. Amin,et al.  Efficacy and tolerability of initial antiretroviral therapy: a systematic review , 2009, AIDS.

[7]  P. Price,et al.  Can we predict neuropathy risk before stavudine prescription in a resource-limited setting? , 2008, AIDS research and human retroviruses.

[8]  V. Calvez,et al.  Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study , 2008, HIV medicine.

[9]  K. Mounzer,et al.  Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  D. Ngare,et al.  Antiretroviral Durability and Tolerability in HIV-Infected Adults Living in Urban Kenya , 2007, Journal of acquired immune deficiency syndromes.

[11]  P. Graaff,et al.  Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens , 2007, AIDS.

[12]  C. Katlama,et al.  Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment , 2007, Expert opinion on pharmacotherapy.

[13]  A. Vibhagool,et al.  Experience with the use of a first‐line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database , 2007, HIV medicine.

[14]  Joseph Quinn,et al.  An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults , 2006, AIDS.

[15]  M. Lipman,et al.  Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals. , 2000, AIDS.